 we report on our fourth quarter and full year 2019 financial results and provide an update on our immuno-inflammatory pipeline. 
 we ended the year with $75 million in cash and investments and anticipate that our current capital will provide a cash runway into the third quarter of 2021 without giving effect to any potential business activities or financing activities. 
 we also report preliminary results from our first in human single ascending and multiple ascending dose trial with ATI-450 in oral small molecule MK2 inhibitor for the treatment of immuno-inflammatory diseases. 
 preliminary results from the second of two pivotal studies from common warts are also reported. 
 we also report on the status of our investigation of the effect of ATI-450 in rheumatoid arthritis.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 